Search

Your search keyword '"Komajda M"' showing total 1,091 results
Start Over Author "Komajda M"
1,091 results on '"Komajda M"'

158. EURObservational Research Programme: Regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)

Author

Maggioni, A.P. Dahlström, U. Filippatos, G. Chioncel, O. Leiro, M.C. Drozdz, J. Fruhwald, F. Gullestad, L. Logeart, D. Fabbri, G. Urso, R. Metra, M. Parissis, J. Persson, H. Ponikowski, P. Rauchhaus, M. Voors, A.A. Nielsen, O.W. Zannad, F. Tavazzi, L. Alonso, A. Ferrari, R. Komajda, M. Wood, D. Manini, M. Taylor, C. Laroche, C. Fiorucci, E. Lucci, D. Gonzini, L. Auer, J. Oberrauner, A. Schumacher, M. Ebner, C. Hallas, A. Espersen, G. Gustafsson, F. Mattsson, N. Egstrup, K. Aagaard, S. Gohr, T. Huld, K. Knudsen, A. Refsgaard, J. Charniot, J. Juillard, A. Pon-Gabrielsen, P. Douna, F. Jondeau, G. Jourdain, P. Michel, L. Hamm, C. Lehinant, S. Rieth, A. Goeing, O. Schultheiss, H.P. Von-Schlippenbach, J. Knollmann, R. Neubüser, C. Katus, H.A. Taeger, T. Zugck, C. Fink, H. Schulz, J. Held, S. Karmann, W. Kreuzer, J. Nitsche, K. Winter, K. Fahnrich, A. Bruederlein, K. Turan, C.H. Berentelg, J. Ittel, T. Rubens, C. Hanke, M. Stoerk, S. Chrysohoou, C. Kaldara, E. Karavidas, A. Margari, R. Matzaraki, V. Nanas, J. Pozios, I. Psarogiannakopoulos, P. Pyrgakis, V. Stefanadis, C. Terrovitis, J. Trikas, A. Xydonas, S. Patrianakos, A. Vardas, P. Douras, A. Nastas, J. Ntertsas, K. Tsaknakis, T. Midi, P. Pajes, G. Moretti, L. Partemi, M. Barberini, F. Branzi, A. Gallelli, I. Grigioni, F. Ionico, T. Pasquale, F. Cas, L. Delmagro, F. Tanghetti, E. Vaccari, A. Mercuro, G. Arcuri, G.M. Marinacci, L. Severini, D. Cosmi, F. Bosi, S. Di Tano, G. Pirelli, S. Ferrari, R. Fucili, A. Minneci, C. Santoro, G.M. Correale, M. Di Biase, M. Buccolieri, M. Mandorla, S. Martinelli, S. Barbiero, M. Giordano, A. Zanelli, E. Agostoni, P. Fiorentini, C. Salvioni, E. Leuzzi, C. Modena, M.G. Reggianini, L. Cobelli, F. Opasich, C. Baldini, P. Romei, M. Pulitano, G. Ruggeri, A. Bologna, F. Piovaccari, G. Brasolin, B. Fedele, F. Merlo, M. Sinagra, G. Albanese, M.C. Miani, D. Linssen, G. Rodijk, E. Pinto, Y. Van Donk, P. Dunselman, P. Lok, D. Brouwers, F. De Jong, R.M. Boen, R. Hole, T. Rasmussen, L. Christiansen and Maggioni, A.P. Dahlström, U. Filippatos, G. Chioncel, O. Leiro, M.C. Drozdz, J. Fruhwald, F. Gullestad, L. Logeart, D. Fabbri, G. Urso, R. Metra, M. Parissis, J. Persson, H. Ponikowski, P. Rauchhaus, M. Voors, A.A. Nielsen, O.W. Zannad, F. Tavazzi, L. Alonso, A. Ferrari, R. Komajda, M. Wood, D. Manini, M. Taylor, C. Laroche, C. Fiorucci, E. Lucci, D. Gonzini, L. Auer, J. Oberrauner, A. Schumacher, M. Ebner, C. Hallas, A. Espersen, G. Gustafsson, F. Mattsson, N. Egstrup, K. Aagaard, S. Gohr, T. Huld, K. Knudsen, A. Refsgaard, J. Charniot, J. Juillard, A. Pon-Gabrielsen, P. Douna, F. Jondeau, G. Jourdain, P. Michel, L. Hamm, C. Lehinant, S. Rieth, A. Goeing, O. Schultheiss, H.P. Von-Schlippenbach, J. Knollmann, R. Neubüser, C. Katus, H.A. Taeger, T. Zugck, C. Fink, H. Schulz, J. Held, S. Karmann, W. Kreuzer, J. Nitsche, K. Winter, K. Fahnrich, A. Bruederlein, K. Turan, C.H. Berentelg, J. Ittel, T. Rubens, C. Hanke, M. Stoerk, S. Chrysohoou, C. Kaldara, E. Karavidas, A. Margari, R. Matzaraki, V. Nanas, J. Pozios, I. Psarogiannakopoulos, P. Pyrgakis, V. Stefanadis, C. Terrovitis, J. Trikas, A. Xydonas, S. Patrianakos, A. Vardas, P. Douras, A. Nastas, J. Ntertsas, K. Tsaknakis, T. Midi, P. Pajes, G. Moretti, L. Partemi, M. Barberini, F. Branzi, A. Gallelli, I. Grigioni, F. Ionico, T. Pasquale, F. Cas, L. Delmagro, F. Tanghetti, E. Vaccari, A. Mercuro, G. Arcuri, G.M. Marinacci, L. Severini, D. Cosmi, F. Bosi, S. Di Tano, G. Pirelli, S. Ferrari, R. Fucili, A. Minneci, C. Santoro, G.M. Correale, M. Di Biase, M. Buccolieri, M. Mandorla, S. Martinelli, S. Barbiero, M. Giordano, A. Zanelli, E. Agostoni, P. Fiorentini, C. Salvioni, E. Leuzzi, C. Modena, M.G. Reggianini, L. Cobelli, F. Opasich, C. Baldini, P. Romei, M. Pulitano, G. Ruggeri, A. Bologna, F. Piovaccari, G. Brasolin, B. Fedele, F. Merlo, M. Sinagra, G. Albanese, M.C. Miani, D. Linssen, G. Rodijk, E. Pinto, Y. Van Donk, P. Dunselman, P. Lok, D. Brouwers, F. De Jong, R.M. Boen, R. Hole, T. Rasmussen, L. Christiansen

Abstract

AimsThe ESC-HF Pilot survey was aimed to describe clinical epidemiology and 1-year outcomes of outpatients and inpatients with heart failure (HF). The pilot phase was also specifically aimed at validating structure, performance, and quality of the data set for continuing the survey into a permanent Registry.MethodsThe ESC-HF Pilot study is a prospective, multicentre, observational survey conducted in 136 Cardiology Centres in 12 European countries selected to represent the different health systems across Europe. All outpatients with HF and patients admitted for acute HF on 1 day per week for eight consecutive months were included. From October 2009 to May 2010, 5118 patients were included: 1892 (37%) admitted for acute HF and 3226 (63%) patients with chronic HF. The all-cause mortality rate at 1 year was 17.4% in acute HF and 7.2% in chronic stable HF. One-year hospitalization rates were 43.9% and 31.9%, respectively, in hospitalized acute and chronic HF patients. Major regional differences in 1-year mortality were observed that could be explained by differences in characteristics and treatment of the patients.ConclusionThe ESC-HF Pilot survey confirmed that acute HF is still associated with a very poor medium-term prognosis, while the widespread adoption of evidence-based treatments in patients with chronic HF seems to have improved their outcome profile. Differences across countries may be due to different local medical practice as well to differences in healthcare systems. This pilot study also offered the opportunity to refine the organizational structure for a long-term extended European network. © 2013 The Author.

Published
2013

159. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

Author

Mancia, G, Fagard, R, Narkiewicz, K, Redon, J, Zanchetti, A, Böhm, M, Christiaens, T, Cifkova, R, De Backer, G, Dominiczak, A, Galderisi, M, Grobbee, D, Jaarsma, T, Kirchhof, P, Kjeldsen, S, Laurent, S, Manolis, A, Nilsson, P, Ruilope, L, Schmieder, R, Sirnes, P, Sleight, P, Viigimaa, M, Waeber, B, Zannad, F, Burnier, M, Ambrosioni, E, Caufield, M, Coca, A, Olsen, M, Tsioufis, C, Van De Borne, P, Zamorano, J, Achenbach, S, Baumgartner, H, Bax, J, Bueno, H, Dean, V, Deaton, C, Erol, C, Ferrari, R, Hasdai, D, Hoes, A, Knuuti, J, Kolh, P, Lancellotti, P, Linhart, A, Nihoyannopoulos, P, Piepoli, M, Ponikowski, P, Tamargo, J, Tendera, M, Torbicki, A, Wijns, W, Windecker, S, Clement, D, Gillebert, T, Rosei, E, Anker, S, Bauersachs, J, Hitij, J, Caulfield, M, De Buyzere, M, De Geest, S, Derumeaux, G, Erdine, S, Farsang, C, Funck Brentano, C, Gerc, V, Germano, G, Gielen, S, Haller, H, Jordan, J, Kahan, T, Komajda, M, Lovic, D, Mahrholdt, H, Ostergren, J, Parati, G, Perk, J, Polonia, J, Popescu, B, Reiner, Ž, Rydén, L, Sirenko, Y, Stanton, A, Struijker Boudier, H, Vlachopoulos, C, Volpe, M, Wood, D, MANCIA, GIUSEPPE, PARATI, GIANFRANCO, Wood, D., Mancia, G, Fagard, R, Narkiewicz, K, Redon, J, Zanchetti, A, Böhm, M, Christiaens, T, Cifkova, R, De Backer, G, Dominiczak, A, Galderisi, M, Grobbee, D, Jaarsma, T, Kirchhof, P, Kjeldsen, S, Laurent, S, Manolis, A, Nilsson, P, Ruilope, L, Schmieder, R, Sirnes, P, Sleight, P, Viigimaa, M, Waeber, B, Zannad, F, Burnier, M, Ambrosioni, E, Caufield, M, Coca, A, Olsen, M, Tsioufis, C, Van De Borne, P, Zamorano, J, Achenbach, S, Baumgartner, H, Bax, J, Bueno, H, Dean, V, Deaton, C, Erol, C, Ferrari, R, Hasdai, D, Hoes, A, Knuuti, J, Kolh, P, Lancellotti, P, Linhart, A, Nihoyannopoulos, P, Piepoli, M, Ponikowski, P, Tamargo, J, Tendera, M, Torbicki, A, Wijns, W, Windecker, S, Clement, D, Gillebert, T, Rosei, E, Anker, S, Bauersachs, J, Hitij, J, Caulfield, M, De Buyzere, M, De Geest, S, Derumeaux, G, Erdine, S, Farsang, C, Funck Brentano, C, Gerc, V, Germano, G, Gielen, S, Haller, H, Jordan, J, Kahan, T, Komajda, M, Lovic, D, Mahrholdt, H, Ostergren, J, Parati, G, Perk, J, Polonia, J, Popescu, B, Reiner, Ž, Rydén, L, Sirenko, Y, Stanton, A, Struijker Boudier, H, Vlachopoulos, C, Volpe, M, Wood, D, MANCIA, GIUSEPPE, PARATI, GIANFRANCO, and Wood, D.

Published
2013

160. [Observations on the management of cardiac failure in ambulatory patients. Results of a survey of cardiologists]

Author

Komajda M, Jb, Bouhour, Philippe Amouyel, Delahaye F, Vicaut E, Croce I, Rougemond E, Vuittenez F, and Leutenegger E

Subjects
Heart Failure, Male, Cardiotonic Agents, Incidence, Adrenergic beta-Antagonists, Age Factors, Cardiology, Digitalis Glycosides, Angiotensin-Converting Enzyme Inhibitors, Middle Aged, Health Surveys, Humans, Female, Practice Patterns, Physicians', Diuretics, Aged
Abstract

An enquiry was undertaken amongst 71 cardiologists in 1999 evaluating 600 ambulatory patients with cardiac failure (64% men; mean age 73 years; NYHA Class I: 9%, Class II: 52%, Class III: 33%, Class IV: 6%). Cardiac failure is commoner in men (81%) before the age of 70. After the age of 80, the tendency is inversed (53% of women). Fifty-two per cent of patients had a history of hospital admission for cardiac failure: 26% in the year before the enquiry (on average 13.1 days' hospital stay). On inclusion, the diagnosis was made 4.2 +/- 4.6 years previously and the patients had been followed up for an average of 3.04 +/- 3.3 years. The diagnosis of cardiac failure was made by the cardiologist (57%), the general practitioner (37%), or another category of physician (6%). Eight per cent of patients were treated with a single drug before inclusion, 22% had a bi-therapy and 70% a polytherapy. The most frequently prescribed drugs were: diuretics (71%), angiotensin converting enzyme (ACE) inhibitors (54%) and digitalis (35%). The prescription of betablockers was only reported in 14% of the population. In the over-80's, only 45% of patients were prescribed ACE inhibitors. These results confirm that ambulatory patients with cardiac failure are mainly in NYHA Classes II and III, that the pathology concerns elderly patients and that it is the cause of recurrent hospital admission. The prescription of diuretics is the main therapy in all NYHA Classes. ACE inhibitors were only prescribed in 2/3 of patients and in less than half of patients over 80 years of age. The prescription of betablockers remains marginal. The reason for the underprescription of recommended drugs (International Recommendations) would justify further investigation.

Published
2001

161. Reduced costs with bisoprolol treatment for heart failure - An economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II)

Author

Bacquet, P, Levy, E, Mcguire, A, Mcmurray, J, Merot, Jl, Paschen, B, Remme, Wj, Szucs, Td, Klein, W, Brunhuber, W, Hofmann, R, Kuhn, P, Nesser, Hj, Slany, J, Weihs, W, Wiedermann, C, Wimmer, H, van Mieghem, W, Boland, J, Chaudron, Jm, Jordaens, L, Melchior, Jp, Aschermann, M, Bruthansl, J, Hradec, M, Kolbel, F, Semrad, B, Haghfelt, T, Hansen, Jf, Goetzsche, Co, Hildebrandt, P, Kassis, E, Rasmussen, V, Rokkedal, J, Thomassen, A, Groundstroem, K, Uusimaa, P, Le Heuzey JY, Aumont, Mc, Aupetit, Jf, Baille, N, Baudouy, P, Belin, A, Bonneau, A, Bonneric, G, Bousser, Jp, Citron, B, Dary, P, Decoulx, E, De Groote, P, Denolle, T, Dievart, F, Duriez, P, Eicher, Jc, Enjuto, G, Ferriere, M, Fournier, E, Garandeau, M, Gauthier, J, Genest, M, Gerbe, A, Godenir, Jp, Guillot, B, Guillot, Jp, Guillot, P, Heno, P, D'Ivernois, C, Jean, M, Kacet, S, Kalle, R, Komajda, M, Lacroix, A, Lallemand, R, Lardoux, H, Marquet, M, Martin, M, Martin, O, Mery, D, Mossaz, R, Mothes, P, Olive, T, Ostorero, M, Paganelli, F, Page, E, Pauly Laubry, C, Puel, J, Rousseau, Jf, Roux, Jj, Schenowitz, A, Sourdais, K, Tremel, F, Verdun, A, Witchiz, S, Wolf, Je, Hombach, V, Assmann, I, Beyer, T, Bischoff, Ko, Darius, H, Ertl, G, Fleck, E, Forster, K, Freytag, F, Gleichmann, U, Haasis, R, Henssge, R, Hey, D, Hesse, P, Hofs, T, Keck, M, Klein, H, Kromer, Et, Kruls Munch, J, Luderitz, B, Maisch, B, Mitrovic, V, Neubauer, S, Osterziel, Kj, Simon, H, Spitzer, Sg, Stohring, R, Taubert, G, Teichmann, W, Theisen, K, Wende, W, Wieser, H, Zotz, R, Bridges, A, Adgey, J, Ambepitiya, G, Boon, N, Boyle, Rm, Cowley, Aj, Cripps, T, Davies, Mk, Dunn, F, Findlay, J, Forsey, P, Fyfe, T, Gould, B, Greenwood, Tw, Hubner, P, Khan, S, Lewis, P, Mackay, A, Maltz, M, Mcarthur, J, Mcleod, A, Mcleod, D, Metcalfe, M, Millar Craig, M, Mills, P, Nelson, Jk, Nicholls, D, Oakley, Gd, Patterson, Dlh, Pohl, Jef, Ray, S, Silke, B, Wilkinson, Pr, Preda, I, Csanady, M, Cserhalmi, L, Edes, I, Gesztesi, T, Karpati, P, Simon, K, Tarjan, J, Fogari, R, Tramarin, R, Galie, N, Giani, P, Milanese, U, Scalvini, S, Scrutinio, D, Sechi, Leonardo Alberto, Tettamanti, F, De Vito, F, Crean, P, Mccann, H, Mulcahy, D, Sugrue, D, van Hoogenhuyze DCA, van der Burgh PH, Ciampricotti, R, van Dantzig JM, Denhartog, Fr, Henneman, Ja, van Kesteren HAM, Kragten, Ja, Liem, Kl, Limburg, A, van der Linde MR, Linssen, Gcm, Pasteuning, H, Penn, Hjam, Van Rossum, P, Schaafsma, Hj, Schelling, A, Sloos, R, Wesdorp, Jcl, Korewicki, J, Achremczyk, P, Czestockowska, E, Dowgird, M, Dyduszynski, A, Gorski, J, Ilmurzynska, K, Janicki, K, Kornacewicz Jach, Z, Kraska, T, Krzeminska Pakula, M, Kuch, J, Nartowicz, E, Petelenz, T, Piwowarska, W, Rawczynska Englert, I, Ruzyllo, W, Swiatecka, G, Tendera, M, Wierzchowiecki, M, Wodniecki, J, Wojciechowoski, D, Wrabec, K, Wysocki, H, Gomes, Rs, Ceia, Mf, Lousada, N, Campos, Jmm, Providencia, La, de Moura ALZC, Marejev, Vj, Aronov, Dm, Arutjunov, Gp, Bart, Bj, Basechikin, Ss, Belenkov, Jn, Beloussov, Jb, Bokeria, Oa, Charchogljan, Ra, Doschytsin, V, Fedorova, Ta, Glezer, Mg, Gorbachenkov, A, Gorshkov, Gospodarenko, Al, Ivashkin, Vt, Ivleva, Aj, Kyrichenko, Aa, Lavrov, Aa, Lazebnik, Lb, Marynov, A, Mazaev, Vp, Polejev, Nr, Shpektor, Sidorenko, Ba, Sobolev, Ke, Starodoubtsev, Ak, Storozhakhov, Gi, Syrkin, Al, Zodionchenko, Vs, Zvereva, Tv, Murin, J, Kaliska, G, Rybar, R, Valle, V, Artaza, M, Conthe, P, Cruz, Jm, Garcia Moll, M, Lopez Sendon JL, Martinez, A, Monzon, F, Ribas, M, Roig, E, Roldan, I, Hoglund, C, Ekdahl, S, Hjelmaeus, L, Lindberg, K, Lofdahl, P, Ulvenstam, G, Warselius, L, Follath, F, Anghern, W, Dubach, P, Erne, P, Gallino, A, Moccetti, T, Jmouro, Av, Dargie, Hj, Erdmann, E, Lechat, P, Sendon, Jll, Mareyev, V, Sadowski, Z, Seabra Gomes RJ, Zannad, F, Wehrlen Grandjean, M, Funck Brentano, C, Hansen, S, Hohnloser, S, Vanoli, E, Jaillon, P, De Baker, G, Dahlstrom, U, Hill, C, Leizorovicz, A, Burgnard, F, Rolland, C, Wiemann, H, Verkenne, P, Arab, T, Cussac, N, Dussous, V, Haise, S, and Funck Brentano, C.

Subjects
H Social Sciences (General), medicine.medical_specialty, Cost-Benefit Analysis, Adrenergic beta-Antagonists, METOPROLOL, Placebo, THERAPY, Indirect costs, Pharmacoeconomics, Pharmacotherapy, RANDOMIZED INTERVENTION TRIAL, PHARMACOECONOMICS, Germany, Health care, Bisoprolol, Humans, Medicine, Outpatient clinic, Prospective Studies, Intensive care medicine, health care economics and organizations, Heart Failure, CARVEDILOL, business.industry, MORTALITY, Diagnosis-related group, United Kingdom, Chemotherapy, Adjuvant, MERIT-HF, HOSPITALIZATION, MINIMIZATION, INHIBITORS, France, Quality-Adjusted Life Years, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract

Background Beta-blockers, used as an adjunctive to diuretics, digoxin and angiotensin converting enzyme inhibitors, improve survival in chronic heart failure. We report a prospectively planned economic analysis of the cost of adjunctive beta-blocker therapy in the second Cardiac Insufficiency BIsoprolol Study (CIBIS II). Methods Resource utilization data (drug therapy, number of hospital admissions, length of hospital stay, ward type) were collected prospectively in all patients in CIBIS . These data were used to determine the additional direct costs incurred, and savings made, with bisoprolol therapy. As well as the cost of the drug, additional costs related to bisoprolol therapy were added to cover the supervision of treatment initiation and titration (four outpatient clinic/office visits). Per them (hospital bed day) costings were carried out for France, Germany and the U.K. Diagnosis related group costings were performed for France and the U.K. Our analyses took the perspective of a third party payer in France and Germany and the National Health Service in the U.K. Results Overall, fewer patients were hospitalized in the bisoprolol group, there were fewer hospital admissions perpatient hospitalized, fewer hospital admissions overall, fewer days spent in hospital and fewer days spent in the most expensive type of ward. As a consequence the cost of care in the bisoprolol group was 5-10% less in all three countries, in the per them analysis, even taking into account the cost of bisoprolol and the extra initiation/up-titration visits. The cost per patient treated in the placebo and bisoprolol groups was FF35 009 vs FF31 762 in France, DM11 563 vs DM10 784 in Germany and pound 4987 vs pound 4722 in the U.K. The diagnosis related group analysis gave similar results. Interpretation Not only did bisoprolol increase survival and reduce hospital admissions in CIBIS II, it also cut the cost of care in so doing. This `win-win' situation of positive health benefits associated with cost savings is Favourable from the point of view of both the patient and health care systems. These findings add further support for the use of beta-blockers in chronic heart failure.

Published
2001

162. Recommendations for exercise testing in chronic heart failure patients

Author

Bjornstad, H, Solal, AC, Dubach, P, Fioretti, PM, Giannuzzi, P, Hambrecht, R, Hellemans, [No Value], McGee, H, Mendes, M, Perk, J, Saner, H, Verres, G, Brutsaert, DL, Cleland, JGF, Dresler, H, Erhardt, L, Ferrari, R, van Gilst, WH, Komajda, M, Madeira, H, Mercadier, JJ, Nieminen, M, Poole-Wilson, PA, Rieger, GAJ, Ruzillo, W, Swedberg, K, and Tavazzi, L

Subjects
6-MINUTE WALK TEST, PROGNOSTIC ASSESSMENT, ANAEROBIC THRESHOLD, FUNCTIONAL-CAPACITY, ACTIVITY QUESTIONNAIRE, VENTILATORY RESPONSE, ANGINA-PECTORIS, DILATED CARDIOMYOPATHY, CHRONIC CARDIAC-FAILURE, PEAK OXYGEN-CONSUMPTION
Published
2001

163. From abstract to impact in cardiovascular research: factors predicting publication and citation

Author

Winnik, S, Raptis, D A, Walker, J H, Hasun, M, Speer, T, Clavien, P A, Komajda, M, Bax, J J, Tendera, M, Fox, K, Van de Werf, F, Mundow, C, Lüscher, Thomas F; https://orcid.org/0000-0002-5259-538X, Ruschitzka, F, Matter, C M, Winnik, S, Raptis, D A, Walker, J H, Hasun, M, Speer, T, Clavien, P A, Komajda, M, Bax, J J, Tendera, M, Fox, K, Van de Werf, F, Mundow, C, Lüscher, Thomas F; https://orcid.org/0000-0002-5259-538X, Ruschitzka, F, and Matter, C M

Abstract

Through a 4-year follow-up of the abstracts submitted to the European Society of Cardiology Congress in 2006, we aimed at identifying factors predicting high-quality research, appraising the quality of the peer review and editorial processes, and thereby revealing potential ways to improve future research, peer review, and editorial work.Methods and resultsAll abstracts submitted in 2006 were assessed for acceptance, presentation format, and average reviewer rating. Accepted and rejected studies were followed for 4 years. Multivariate regression analyses of a representative selection of 10% of all abstracts (n= 1002) were performed to identify factors predicting acceptance, subsequent publication, and citation. A total of 10 020 abstracts were submitted, 3104 (31%) were accepted for poster, and 701 (7%) for oral presentation. At Congress level, basic research, a patient number >/= 100, and prospective study design were identified as independent predictors of acceptance. These factors differed from those predicting full-text publication, which included academic affiliation. The single parameter predicting frequent citation was study design with randomized controlled trials reaching the highest citation rates. The publication rate of accepted studies was 38%, whereas only 24% of rejected studies were published. Among published studies, those accepted at the Congress received higher citation rates than rejected ones.ConclusionsResearch of high quality was determined by study design and largely identified at Congress level through blinded peer review. The scientometric follow-up revealed a marked disparity between predictors of full-text publication and those predicting citation or acceptance at the Congress.

Published
2012

165. The future of clinical trials in secondary prevention after acute coronary syndromes

Author

Bueno, H., Armstrong, P.W., Buxton, M.J., Danchin, N., Lubsen, J., Roland, E., Verheugt, F.W.A., Zalewski, A., Jackson, N., Komajda, M., Steg, P.G., Bueno, H., Armstrong, P.W., Buxton, M.J., Danchin, N., Lubsen, J., Roland, E., Verheugt, F.W.A., Zalewski, A., Jackson, N., Komajda, M., and Steg, P.G.

Abstract

Contains fulltext : 97431.pdf (publisher's version ) (Closed access)

Published
2011

166. Effect of Nesiritide in Patients with Acute Decompensated Heart Failure

Author

OConnor, C.M., Starling, R.C., Hernandez, A.F., Armstrong, P.W., Dickstein, K., Hasselblad, V., Heizer, G.M., Komajda, M., Massie, B.M., McMurray, J.J. V., Nieminen, M.S., Reist, C.J., Rouleau, J.L., Swedberg, K., Adams, K.F., Anker, S.D., Atar, D., Battler, A., Botero, R., Bohidar, N.R., Butler, J., Clausell, N., Corbalan, R., Costanzo, M.R., Dahlström, Ulf, Deckelbaum, L.I., Diaz, R., Dunlap, M.E., Ezekowitz, J.A., Feldman, D., Felker, G.M., Fonarow, G.C., Gennevois, D., Gottlieb, S.S., Hill, J.A., Hollander, J.E., Howlett, J.G., Hudson, M.P., Kociol, R.D., Krum, H., Laucevicius, A., Levy, W.C., Mendez, G.F., Metra, M., Mittal, S., Oh, B.-H., Pereira, N.L., Ponikowski, P., Wilson, W.H., Tanomsup, S., Teerlink, J.R., Triposkiadis, F., Troughton, R.W., Voors, A.A., Whellan, D.J., Zannad, F., Califf, R.M., OConnor, C.M., Starling, R.C., Hernandez, A.F., Armstrong, P.W., Dickstein, K., Hasselblad, V., Heizer, G.M., Komajda, M., Massie, B.M., McMurray, J.J. V., Nieminen, M.S., Reist, C.J., Rouleau, J.L., Swedberg, K., Adams, K.F., Anker, S.D., Atar, D., Battler, A., Botero, R., Bohidar, N.R., Butler, J., Clausell, N., Corbalan, R., Costanzo, M.R., Dahlström, Ulf, Deckelbaum, L.I., Diaz, R., Dunlap, M.E., Ezekowitz, J.A., Feldman, D., Felker, G.M., Fonarow, G.C., Gennevois, D., Gottlieb, S.S., Hill, J.A., Hollander, J.E., Howlett, J.G., Hudson, M.P., Kociol, R.D., Krum, H., Laucevicius, A., Levy, W.C., Mendez, G.F., Metra, M., Mittal, S., Oh, B.-H., Pereira, N.L., Ponikowski, P., Wilson, W.H., Tanomsup, S., Teerlink, J.R., Triposkiadis, F., Troughton, R.W., Voors, A.A., Whellan, D.J., Zannad, F., and Califf, R.M.

Abstract

Background Nesiritide is approved in the United States for early relief of dyspnea in patients with acute heart failure. Previous meta-analyses have raised questions regarding renal toxicity and the mortality associated with this agent. Methods We randomly assigned 7141 patients who were hospitalized with acute heart failure to receive either nesiritide or placebo for 24 to 168 hours in addition to standard care. Coprimary end points were the change in dyspnea at 6 and 24 hours, as measured on a 7-point Likert scale, and the composite end point of rehospitalization for heart failure or death within 30 days. Results Patients randomly assigned to nesiritide, as compared with those assigned to placebo, more frequently reported markedly or moderately improved dyspnea at 6 hours (44.5% vs. 42.1%, P = 0.03) and 24 hours (68.2% vs. 66.1%, P = 0.007), but the prespecified level for significance (P = 0.005 for both assessments or Pd less than= 0.0025 for either) was not met. The rate of rehospitalization for heart failure or death from any cause within 30 days was 9.4% in the nesiritide group versus 10.1% in the placebo group (absolute difference, -0.7 percentage points; 95% confidence interval [CI], -2.1 to 0.7; P = 0.31). There were no significant differences in rates of death from any cause at 30 days (3.6% with nesiritide vs. 4.0% with placebo; absolute difference, -0.4 percentage points; 95% CI, -1.3 to 0.5) or rates of worsening renal function, defined by more than a 25% decrease in the estimated glomerular filtration rate (31.4% vs. 29.5%; odds ratio, 1.09; 95% CI, 0.98 to 1.21; P = 0.11). Conclusions Nesiritide was not associated with an increase or a decrease in the rate of death and rehospitalization and had a small, nonsignificant effect on dyspnea when used in combination with other therapies. It was not associated with a worsening of renal function, but it was associated with an increase in rates of hypotension. On the basis of these results, nesiritide cannot b

Published
2011
Full Text
View/download PDF

167. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Author

Home, P.D., Pocock, S.J., Beck-Nielsen, H., Curtis, P.S., Gomis, R., Hanefeld, M., Jones, N.P., Komajda, M., McMurray, J.J., Home, P.D., Pocock, S.J., Beck-Nielsen, H., Curtis, P.S., Gomis, R., Hanefeld, M., Jones, N.P., Komajda, M., and McMurray, J.J.

Abstract

Background: Rosiglitazone is an insulin sensitiser used in combination with metformin, a sulfonylurea, or both, for lowering blood glucose in people with type 2 diabetes. We assessed cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea compared with the combination of the two over 5-7 years of follow-up. We also assessed comparative safety. Methods: In a multicentre, open-label trial, 4447 patients with type 2 diabetes on metformin or sulfonylurea monotherapy with mean haemoglobin A 1c (HbA 1c) of 7·9% were randomly assigned to addition of rosiglitazone (n=2220) or to a combination of metformin and sulfonylurea (active control group, n=2227). The primary endpoint was cardiovascular hospitalisation or cardiovascular death, with a hazard ratio (HR) non-inferiority margin of 1·20. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00379769. Findings: 321 people in the rosiglitazone group and 323 in the active control group experienced the primary outcome during a mean 5·5-year follow-up, meeting the criterion of non-inferiority (HR 0·99, 95% CI 0·85-1·16). HR was 0·84 (0·59-1·18) for cardiovascular death, 1·14 (0·80-1·63) for myocardial infarction, and 0·72 (0·49-1·06) for stroke. Heart failure causing admission to hospital or death occurred in 61 people in the rosiglitazone group and 29 in the active control group (HR 2·10, 1·35-3·27, risk difference per 1000 person-years 2·6, 1·1-4·1). Upper and distal lower limb fracture rates were increased mainly in women randomly assigned to rosiglitazone. Mean HbA 1c was lower in the rosiglitazone group than in the control group at 5 years. Interpretation: Addition of rosiglitazone to glucose-lowering therapy in people with type 2 diabetes is confirmed to increase the risk of heart failure and of some fractures, mainly in women. Although the data are inconclusive about any possible effect on myocardial infarction, rosiglitazone does not increase, Group Author(s): RECORD Study TeamFolke Sjöberg, Linköping University

Published
2009
Full Text
View/download PDF

168. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial

Author

Lechat, P, Brunhuber, Kw, Hofmann, R, Kuhn, P, Nesser, Hj, Slany, J, Weihs, W, Wiedermann, C, Wimmer, H, van Mieghem, W, Boland, J, Chaudron, Jm, Jordaens, L, Melchior, Jp, Aschermann, M, Bruthansl, J, Hradec, M, Kolbel, F, Semrad, B, Haghfelt, T, Fischer Hansen, J, Goetzsche, Co, Hildebrandt, P, Kassis, E, Rasmussen, V, Rokkedal, J, Thomassen, A, Groundstroem, K, Uusimaa, P, Le Heuzey JY, Aumont, Mc, Aupetit, Jf, Baille, N, Baudouy, P, Belin, A, Bonneau, A, Bonneric, G, Bousser, Jp, Citron, B, Dary, P, Decoulx, E, De Groote, P, Denolle, T, Dievart, F, Duriez, P, Eicher, Jc, Enjuto, G, Ferriere, M, Fournier, E, Garandeau, M, Gauthier, J, Genest, M, Gerbe, A, Godenir, Jp, Guillot, B, Guillot, Jp, Guillot, P, Heno, P, D'Ivernois, C, Jean, M, Kacet, S, Kalle, R, Komajda, M, Lacroix, A, Lallemand, R, Lardoux, H, Marquet, M, Martin, M, Martin, O, Mery, D, Mossaz, R, Mothes, P, Olive, T, Ostorero, M, Paganelli, F, Page, E, Pauly Laubry, C, Puel, J, Rousseau, Jf, Roux, Jj, Schenowitz, A, Sourdais, K, Tremel, F, Verdun, A, Witchiz, S, Wolf, Je, Hombach, V, Assmann, I, Beyer, T, Bischoff, Ko, Darius, H, Ertl, G, Fleck, E, Forster, K, Freytag, F, Gleichmann, U, Haasis, R, Henssge, R, Hey, D, Hesse, P, Hofs, T, Keck, M, Klein, H, Kromer, Et, Kruls Munch, J, Luderitz, B, Maisch, B, Mitrovic, V, Neubauer, S, Osterziel, Kj, Simon, H, Spitzer, Sg, Stohring, R, Taubert, G, Teichmann, W, Theisen, K, Wende, W, Wieser, H, Zotz, R, Preda, I, Csanady, M, Cserhalmi, L, Edes, I, Gesztesi, T, Karpati, P, Simon, K, Tarjan, J, Fogari, R, Tramarin, R, Galie, N, Giani, P, Milanese, U, Scalvini, S, Scrutinio, D, Sechi, Leonardo Alberto, Tettamanti, F, De Vito, F, Crean, P, Mccann, H, Mulcahy, D, Sugrue, D, van Hoogenhuyze DCA, van der Burgh PH, Ciampricotti, R, van Dantzig JM, Denhartog, Fr, Henneman, Ja, van Kesteren HAM, Kragten, Ja, Liem, Kl, Limburg, A, van der Linde MR, Linssen, Gcm, Pasteuning, H, Penn, Hjam, Van Rossum, P, Schaafsma, Hj, Schelling, A, Sloos, R, Wesdorp, Jcl, Korewicki, J, Achremczyk, P, Czestockowska, E, Dowgird, M, Dyduszynski, A, Gorski, J, Ilmurzynska, K, Janicki, K, Kornacewicz Jach, Z, Kraska, T, Krzeminska Pakula, M, Kuch, J, Nartowicz, E, Petelenz, T, Piwowarska, W, Rawczynska Englert, I, Ruzyllo, W, Swiatecka, G, Tendera, M, Wierzchowiecki, M, Wodniecki, J, Wojciechowoski, D, Wrabec, K, Wysocki, H, Gomes, Rs, Ceia, Mf, Lousada, N, Campos, Jmm, Providencia, La, de Moura ALZC, Marejev, Vj, Aronov, Dm, Arutjunov, Gp, Bart, Bj, Basechikin, Ss, Belenkov, Jn, Beloussov, Jb, Bokeria, Oa, Charchogljan, Ra, Doschytsin, V, Fedorova, Ta, Glezer, Mg, Gorbachenkov, A, Gorshkov, Va, Gospodarenko, Al, Ivashkin, Vt, Ivleva, Aj, Kyrichenko, Aa, Lavrov, Aa, Lazebnik, Lb, Marynov, A, Mazaev, Vp, Polejev, Nr, Shpektor, A, Sidorenko, Ba, Sobolev, Ke, Starodoubtsev, Ak, Storozhakhov, Gi, Syrkin, Al, Zodionchenko, Vs, Zvereva, Tv, Murin, J, Kaliska, G, Rybar, R, Valle, V, Artaza, M, Conthe, P, Cruz, Jm, Garcia Moll, M, Lopez Sendon JL, Martinez, A, Monzon, F, Ribas, M, Roig, E, Roldan, I, Hoglund, C, Ekdahl, S, Hjelmaeus, L, Lindberg, K, Lofdahl, P, Ulvenstam, G, Warselius, L, Follath, F, Anghern, W, Dubach, P, Erne, P, Gallino, A, Moccetti, T, Bridges, A, Adgey, J, Ambepitiya, G, Boon, N, Boyle, Rm, Cowley, Aj, Cripps, T, Davies, Mk, Dunn, F, Findlay, J, Forsey, P, Fyfe, T, Gould, B, Greenwood, Tw, Hubner, P, Khan, S, Lewis, P, Mackay, A, Maltz, M, Mcarthur, J, Mcleod, A, Mcleod, D, Metcalfe, M, Millar Craig, M, Mills, P, Nelson, Jk, Nicholls, D, Oakley, Gd, Patterson, Dlh, Pohl, Jef, Ray, S, Silke, B, Wilkinson, Pr, and Jmouro, Av

Published
1999

170. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

Author

Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J., Ponikowski, P., Poole-Wilson, P.A., Stromberg, A., Veldhuisen, D.J. van, Atar, D., Hoes, A.W., Keren, A., Mebazaa, A., Nieminen, M., Priori, S.G., Swedberg, K., Vahanian, A., Camm, J., De Caterina, R., Dean, V., Funck-Brentano, C., Hellemans, I., Kristensen, S.D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J.L., Auricchio, A., Bax, J.J., Bohm, M., Corra, U., Bella, P. della, Elliott, P.M., Follath, F., Gheorghiade, M., Hasin, Y., Hernborg, A., Jaarsma, T., Komajda, M., Kornowski, R., Piepoli, M., Prendergast, B., Tavazzi, L., Vachiery, J.L., Verheugt, F.W.A., Zannad, F., Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J., Ponikowski, P., Poole-Wilson, P.A., Stromberg, A., Veldhuisen, D.J. van, Atar, D., Hoes, A.W., Keren, A., Mebazaa, A., Nieminen, M., Priori, S.G., Swedberg, K., Vahanian, A., Camm, J., De Caterina, R., Dean, V., Funck-Brentano, C., Hellemans, I., Kristensen, S.D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J.L., Auricchio, A., Bax, J.J., Bohm, M., Corra, U., Bella, P. della, Elliott, P.M., Follath, F., Gheorghiade, M., Hasin, Y., Hernborg, A., Jaarsma, T., Komajda, M., Kornowski, R., Piepoli, M., Prendergast, B., Tavazzi, L., Vachiery, J.L., Verheugt, F.W.A., and Zannad, F.

Abstract

Contains fulltext : 70465.pdf (publisher's version ) (Closed access)

Published
2008

171. New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: Results of the EuroHeart Failure Survey

Author

Rivero-Ayerza, M. (Maximo), Scholte op Reimer, W.J.M. (Wilma), Lenzen, M.J. (Mattie), Theuns, D.A.M.J. (Dominic), Jordaens, L.J.L.M. (Luc), Komajda, M. (Michel), Follath, F., Swedberg, K. (Karl), Cleland, J.G.F. (John), Rivero-Ayerza, M. (Maximo), Scholte op Reimer, W.J.M. (Wilma), Lenzen, M.J. (Mattie), Theuns, D.A.M.J. (Dominic), Jordaens, L.J.L.M. (Luc), Komajda, M. (Michel), Follath, F., Swedberg, K. (Karl), and Cleland, J.G.F. (John)

Abstract

Aims: The prognostic significance of atrial fibrillation (AF) in hospitalized patients with heart failure (HF) remains poorly understood. To evaluate in what way AF and its different modes of presentation affect the in-hospital mortality in patients admitted with HF. Methods and results: The EuroHeart Failure Survey was conducted to ascertain how hospitalized HF patients are managed in Europe. The survey enrolled patients over a 6-week period in 115 hospitals from 24 countries. For this analysis, patients were categorized into three groups according to the type of AF, previous AF (patients known to have had AF prior to admission), new-onset AF (no previous AF with AF diagnosed during hospitalization), and no AF (no previous AF and no AF during hospitalization). Clinical variables, duration of hospitalization, and in-hospital survival status were assessed and compared among groups. Of the 10 701 patients included in the s

Published
2008
Full Text
View/download PDF

172. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II

Author

Komajda, M, Hanon, O, Hochadel, M, Lopez-Sendon, J L, Follath, F, Ponikowski, P, Harjola, V P, Drexler, H, Dickstein, K, Tavazzi, L, Nieminen, M, Komajda, M, Hanon, O, Hochadel, M, Lopez-Sendon, J L, Follath, F, Ponikowski, P, Harjola, V P, Drexler, H, Dickstein, K, Tavazzi, L, and Nieminen, M

Abstract

Aims International guidelines are frequently not implemented in the elderly population with heart failure (HF). This study determined the management of octogenarians with HF enrolled in Euro Heart Failure Survey II (EHFS II) (2004-05). Methods and results We compared the clinical profile, 12 month outcomes, and management modalities between 741 octogenarians (median age 83.7 years) and 2836 younger patients (median age 68.4 years) hospitalized for acute/decompensated HF. Management modalities were also compared with those observed in EHFS I (2000-01). Female gender, new onset HF (de novo), hypertension, atrial fibrillation, co-morbidities, disabilities, and low quality of life were more common in the elderly (all P < 0.001). Mortality rates during hospital stay and during 12 months after discharge were increased in octogenarians (10.7 vs. 5.6% and 28.4 vs. 18.5%, P < 0.001). Underuse and underdosage of medications recommended for HF were observed in the elderly. However, a significant improvement was observed when compared with EHFS I both in the overall HF octogenarian population and in the subgroup with ejection fraction ≤45% for prescription rates of ACE-I/ARBs, beta-blockers, and aldosterone antagonists at discharge (82 vs. 71%; 56 vs. 29%; 54 vs. 18.5%, respectively, all P < 0.01), as well as for recommended combinations and dosage. Prescription rates remained stable for 12 months after discharge in survivors. Conclusion Our study confirms that the contemporary management of very elderly patients with HF remains suboptimal but that the situation is improving

Published
2008

173. New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey

Author

Rivero-Ayerza, M, Scholte op Reimer, W, Lenzen, M, Theuns, D A, Jordaens, L, Komajda, M, Follath, F, Swedberg, K, Cleland, J G, Rivero-Ayerza, M, Scholte op Reimer, W, Lenzen, M, Theuns, D A, Jordaens, L, Komajda, M, Follath, F, Swedberg, K, and Cleland, J G

Abstract

Aims The prognostic significance of atrial fibrillation (AF) in hospitalized patients with heart failure (HF) remains poorly understood. To evaluate in what way AF and its different modes of presentation affect the in-hospital mortality in patients admitted with HF. Methods and results The EuroHeart Failure Survey was conducted to ascertain how hospitalized HF patients are managed in Europe. The survey enrolled patients over a 6-week period in 115 hospitals from 24 countries. For this analysis, patients were categorized into three groups according to the type of AF, previous AF (patients known to have had AF prior to admission), new-onset AF (no previous AF with AF diagnosed during hospitalization), and no AF (no previous AF and no AF during hospitalization). Clinical variables, duration of hospitalization, and in-hospital survival status were assessed and compared among groups. Of the 10 701 patients included in the survey; 6027 (57%) had no AF, 3673 (34%) had previous AF, and 1001 (9%) had new-onset AF. Patients with new-onset AF had a longer stay in the intensive care unit (ICU) when compared with previous AF and no AF patients (mean 2.6 ± 5.3, 1.2 ± 3.5, and 1.5 ± 4.1 days, respectively; P < 0.001). In-hospital mortality was higher among patients with new-onset AF when compared with previous AF or no AF patients (12, 7, and 7% respectively; P < 0.001). After adjusting for multiple clinical variables, new-onset AF (not previous AF) was an independent predictor of in-hospital mortality (odds ratio 1.53, 95% CI 1.1-2.0). Conclusion In hospitalized patients with HF, new-onset AF is an independent predictor of in-hospital mortality and a longer ICU and hospital stay

Published
2008

174. Accelerating progress on non-communicable diseases

Author

Sacco, RL, primary, Smith, SC, additional, Holmes, D, additional, Shurin, S, additional, Brawley, O, additional, Cazap, E, additional, Glass, R, additional, Komajda, M, additional, Koroshetz, W, additional, Mayer-Davis, E, additional, Mbanya, JC, additional, Sledge, G, additional, and Varmus, H, additional

Published
2013
Full Text
View/download PDF

180. Gender-Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in Europe. A Report From the Euro Heart Survey on Atrial Fibrillation

Author

Dagres, N. Nieuwlaat, R. Vardas, P.E. Andresen, D. Lévy, S. Cobbe, S. Kremastinos, D.Th. Breithardt, G. Cokkinos, D.V. Crijns, H.J.G.M. Camm, A.J. Davies, W. Capucci, A. Olsson, B. Aliot, E. Le Heuzey, J.-Y. Santini, M. Manini, M. Bramley, C. Laforest, V. Taylor, C. Del Gaiso, S. Huber, K. De Backer, G. Sirakova, V. Cerbak, R. Thayssen, P. Lehto, S. Blanc, J.-J. Delahaye, F. Kobulia, B. Zeymer, U. Karlocai, K. Graham, I. Shelley, E. Behar, S. Maggioni, A. Gonc¸alves, L. Grabauskiene, V. Asmussen, I. Deckers, J. Stepinska, J. Mareev, V. Vasiljevic, Z. Riecansky, I. Kenda, M.F. Alonso, A. Lopez-Sendon, J.L. Rosengren, A. Buser, P. Okay, T. Sychov, O. Fox, K. Schofield, P. Simoons, M. Wood, D. Battler, A. Boersma, E. Fox, K. Komajda, M. McGregor, K. Mulder, B. Priori, S. Ryde´n, L. Vahanian, A. Wijns, W. Sanofi-Aventis Grigoryan, S.V. Apetyan, I. Aroyan, S. Azarapetyan, L. Anvari, A. Gottsauner-Wolf, M. Pfaffenberger, S. Aydinkoc, K. Kalla, K. Penka, M. Drexel, H. Langer, P. Pierard, L.A. Legrand, V. Blommaert, D. Schroeder, E. Mancini, I. Geelen, P. Brugada, P. De Zutter, M. Vrints, C. Vercammen, M. Morissens, M. Borisov, B. Petrov, V.A. Marinova, M. Assen, A. Goudev, R. Peychev, Y. Stoyanovsky, V. Stoynev, E. Kranjcevic, S. Moutiris, J. Ioannides, M. Evequoz, D. Spacilova, J. Novak, M. Eisenberger, M. Mullerova, J. Kautzner, J. Riedlbauchova, L. Petru`, J. Taborsky, M. Cappelen, H. Sharaf, Y.A. Ibrahim, B.S.S. Tammam, K. Saad, A. Elghawaby, H. Sherif, H.Z. Farouk, H. Mielke, A. Engelen, M. Kirchhof, P. Zimmermann, P. Aviles, F.F. Rubio, J. Malpartida, F. Corona, M. Sanchez, L.T. Miguel, J. Herrera, L. Quesada, A. Garcia, A.J.M. Gonzalez, C.S. Juango, M.S.A. Berjon-Reyero, J. Alegret, J.M. Fernandez, J.M.C. Carrascosa, C. Romero, R.A.F. Lara, M.G. Sendon, J.L.L. de Diego, J.J.G. Martin, L.S. Irurita, M. Guttierez, N.H. Rubio, J.R.S. Antorrena, I. Paves, A.B. Salvador, A. Orriach, M.D. Garcia, A.A. Epelde, F. Martinez, V.B. Sanchez, A.B. Galvez, C.P. Rivero, R.F. Madri and Dagres, N. Nieuwlaat, R. Vardas, P.E. Andresen, D. Lévy, S. Cobbe, S. Kremastinos, D.Th. Breithardt, G. Cokkinos, D.V. Crijns, H.J.G.M. Camm, A.J. Davies, W. Capucci, A. Olsson, B. Aliot, E. Le Heuzey, J.-Y. Santini, M. Manini, M. Bramley, C. Laforest, V. Taylor, C. Del Gaiso, S. Huber, K. De Backer, G. Sirakova, V. Cerbak, R. Thayssen, P. Lehto, S. Blanc, J.-J. Delahaye, F. Kobulia, B. Zeymer, U. Karlocai, K. Graham, I. Shelley, E. Behar, S. Maggioni, A. Gonc¸alves, L. Grabauskiene, V. Asmussen, I. Deckers, J. Stepinska, J. Mareev, V. Vasiljevic, Z. Riecansky, I. Kenda, M.F. Alonso, A. Lopez-Sendon, J.L. Rosengren, A. Buser, P. Okay, T. Sychov, O. Fox, K. Schofield, P. Simoons, M. Wood, D. Battler, A. Boersma, E. Fox, K. Komajda, M. McGregor, K. Mulder, B. Priori, S. Ryde´n, L. Vahanian, A. Wijns, W. Sanofi-Aventis Grigoryan, S.V. Apetyan, I. Aroyan, S. Azarapetyan, L. Anvari, A. Gottsauner-Wolf, M. Pfaffenberger, S. Aydinkoc, K. Kalla, K. Penka, M. Drexel, H. Langer, P. Pierard, L.A. Legrand, V. Blommaert, D. Schroeder, E. Mancini, I. Geelen, P. Brugada, P. De Zutter, M. Vrints, C. Vercammen, M. Morissens, M. Borisov, B. Petrov, V.A. Marinova, M. Assen, A. Goudev, R. Peychev, Y. Stoyanovsky, V. Stoynev, E. Kranjcevic, S. Moutiris, J. Ioannides, M. Evequoz, D. Spacilova, J. Novak, M. Eisenberger, M. Mullerova, J. Kautzner, J. Riedlbauchova, L. Petru`, J. Taborsky, M. Cappelen, H. Sharaf, Y.A. Ibrahim, B.S.S. Tammam, K. Saad, A. Elghawaby, H. Sherif, H.Z. Farouk, H. Mielke, A. Engelen, M. Kirchhof, P. Zimmermann, P. Aviles, F.F. Rubio, J. Malpartida, F. Corona, M. Sanchez, L.T. Miguel, J. Herrera, L. Quesada, A. Garcia, A.J.M. Gonzalez, C.S. Juango, M.S.A. Berjon-Reyero, J. Alegret, J.M. Fernandez, J.M.C. Carrascosa, C. Romero, R.A.F. Lara, M.G. Sendon, J.L.L. de Diego, J.J.G. Martin, L.S. Irurita, M. Guttierez, N.H. Rubio, J.R.S. Antorrena, I. Paves, A.B. Salvador, A. Orriach, M.D. Garcia, A.A. Epelde, F. Martinez, V.B. Sanchez, A.B. Galvez, C.P. Rivero, R.F. Madri

Abstract

Objectives: This study sought to investigate gender-related differences in patients with atrial fibrillation (AF) in Europe. Background: Gender-related differences may play a significant role in AF. Methods: We analyzed the data of 5,333 patients (42% female) enrolled in the Euro Heart Survey on Atrial Fibrillation. Results: Compared with men, the women were older, had a lower quality of life (QoL), had more comorbidities, more often had heart failure (HF) with preserved left ventricular systolic function (18% vs. 7%, p < 0.001), and less often had HF with systolic dysfunction (17% vs. 26%, p < 0.001). Among patients with typical AF symptoms (56% of women, 49% of men), there was no gender-related difference in the choice of rate or rhythm control. Among patients with atypical or no symptoms (44% of women, 51% of men), women less frequently underwent rhythm control (39% vs. 51%, p < 0.001) than did men. Women underwent less electrical cardioversion (22% vs. 28%, p < 0.001). Prescription of oral anticoagulants was identical (65%) in both genders. One-year outcome was similar except that women had a higher chance for stroke (odds ratio 1.83 in multivariable regression analysis, p = 0.019). Conclusions: Women with AF had more comorbidities, more HF with preserved systolic function, and a lower QoL than men. In the large group with atypical or no symptoms, women were treated appropriately more conservatively with less rhythm control than men. Women had a higher chance for stroke. Long-term QoL changes and other morbidities and mortality were similar. © 2007 American College of Cardiology Foundation.

Published
2007

181. Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis.

Author

Berry, C., Poppe, K. K., Gamble, G. D., Earle, N. J., Ezekowitz, J. A., Squire, I. B., McMurray, J. J. V., McAlister, F. A., Komajda, M., Swedberg, K., Maggioni, A. P., Ahmed, A., Whalley, G. A., Doughty, R. N., and Tarantini, L.

Subjects
PROGNOSTIC tests, ANEMIA, HEART failure patients, EJECTION (Psychology), META-analysis, PATIENTS
Abstract

Background: Anaemia is common among patients with heart failure (HF) and is an important prognostic marker. Aim: We sought to determine the prognostic importance of anaemia in a large multinational pooled dataset of prospectively enrolled HF patients, with the specific aim to determine the prognostic role of anaemia in HF with preserved and reduced ejection fraction (HF-PEF and HF-REF, respectively). Design: Individual person data meta-analysis. Methods: Patients with haemoglobin (Hb) data fromthe MAGGIC dataset were used. Anaemia was defined as Hb<120 g/l in women and <130 g/l in men. HF-PEF was defined as EF≥50%; HF-REF was EF<50%. Cox proportional hazard modelling, with adjustment for clinically relevant variables, was undertaken to investigate factors associated with 3-year all-cause mortality. Results: Thirteen thousand two hundred and ninety-five patients with HF from 19 studies (9887 with HF-REF and 3408 with HF-PEF). The prevalence of anaemia was similar among those with HF-REF and HF-PEF (42.8 and 41.6% respectively). Compared with patients with normal Hb values, those with anaemia were older, were more likely to have diabetes, ischaemic aetiology, New York Heart Association class IV symptoms, lower estimated glomerular filtration rate and were more likely to be taking diuretic and less likely to be taking a beta-blocker. Patients with anaemia had higher all-cause mortality (adjusted hazard ratio [aHR] 1.38, 95% confidence interval [CI] 1.25-1.51), independent of EF group: aHR 1.67 (1.39-1.99) in HF-PEF and aHR 2.49 (2.13-2.90) in HF-REF. Conclusions: Anaemia is an adverse prognostic factor in HF irrespective of EF. The prognostic importance of anaemia was greatest in patients with HF-REF. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

183. Penetrance of familial hypertrophic cardiomyopathy

Author

Charron, P., Carrier, L., Dubourg, O., Tesson, F., Desnos, M., Richard, P., Gisèle Bonne, Guicheney, P., Hainque, B., Bouhour, J. B., Mallet, A., Feingold, J., Schwartz, K., and Komajda, M.

Subjects
Adult, Chromosome Aberrations, Male, Adolescent, Genotype, Genetic Linkage, DNA Mutational Analysis, Chromosome Disorders, Genetic Counseling, Cardiomyopathy, Hypertrophic, Middle Aged, Phenotype, Child, Preschool, Humans, Female, Child, Aged, Genes, Dominant
Abstract

Familial hypertrophic cardiomyopathy (FHC) is an autosomal dominant cardiac disease for which the penetrance remains a much-debated issue. Since the recent identification of the genes involved in the disease, the penetrance of FHC has not been reassessed in a large genotyped population. The aim of our study was therefore to evaluate it, according to age and sex, in ten families with previously identified mutations. Among 178 individuals we studied, 90 were genetically affected (9 different mutations in 3 genes). We found that penetrance, assessed by classical echocardiographic and electrocardiographic criteria, was (1) incomplete: 69%; (2) age-related: 55% between 10 and 29 years old, 75% between 30 and 49 y. and 95% over 50 y.; (3) greater in males than in females: 77% vs 58%, age-adjusted odds ratio: 3.98, CI 95%: 1.34 to 11,48; (4) similar for the genes analyzed. The consequences of these results for genetic counseling and linkage analyses are discussed.

Published
1997

186. Poster session 3

Author

Nanka, O., primary, Krejci, E., additional, Pesevski, Z., additional, Sedmera, D., additional, Smart, N., additional, Rossdeutsch, A., additional, Dube, K. N., additional, Riegler, J., additional, Price, A. N., additional, Taylor, A., additional, Muthurangu, V., additional, Turner, M., additional, Lythgoe, M. F., additional, Riley, P. R., additional, Kryvorot, S., additional, Vladimirskaya, T., additional, Shved, I., additional, Schwarzl, M., additional, Seiler, S., additional, Huber, S., additional, Steendijk, P., additional, Maechler, H., additional, Truschnig-Wilders, M., additional, Pieske, B., additional, Post, H., additional, Caprio, C., additional, Baldini, A., additional, Chiavacci, E., additional, Dolfi, L., additional, Verduci, L., additional, Meghini, F., additional, Cremisi, F., additional, Pitto, L., additional, Kuan, T.-C., additional, Chen, M.-C., additional, Yang, T.-H., additional, Wu, W.-T., additional, Lin, C. S., additional, Rai, H., additional, Kumar, S., additional, Sharma, A. K., additional, Mastana, S., additional, Kapoor, A., additional, Pandey, C. M., additional, Agrawal, S., additional, Sinha, N., additional, Orlowska-Baranowska, E. H., additional, Placha, G., additional, Gora, J., additional, Baranowski, R., additional, Abramczuk, E., additional, Hryniewiecki, T., additional, Gaciong, Z., additional, Verschuren, J. J. W., additional, Wessels, J. A. M., additional, Trompet, S., additional, Stott, D. J., additional, Sattar, N., additional, Buckley, B., additional, Guchelaar, H. J., additional, Jukema, J. W., additional, Gharanei, M., additional, Hussain, A., additional, Mee, C. J., additional, Maddock, H. L., additional, Wijnen, W. J., additional, Van Den Oever, S., additional, Van Der Made, I., additional, Hiller, M., additional, Tijsen, A. J., additional, Pinto, Y. M., additional, Creemers, E. E., additional, Nikulina, S. U. Y., additional, Chernova, A., additional, Petry, A., additional, Rzymski, T., additional, Kracun, D., additional, Riess, F., additional, Pike, L., additional, Harris, A. L., additional, Gorlach, A., additional, Katare, R., additional, Oikawa, A., additional, Riu, F., additional, Beltrami, A. P., additional, Cesseli, D., additional, Emanueli, C., additional, Madeddu, P., additional, Zaglia, T., additional, Milan, G., additional, Franzoso, M., additional, Pesce, P., additional, Sarais, C., additional, Sandri, M., additional, Mongillo, M., additional, Butler, T. J., additional, Seymour, A.-M. L., additional, Ashford, D., additional, Jaffre, F., additional, Bussen, M., additional, Flohrschutz, I., additional, Martin, G. R., additional, Engelhardt, S., additional, Kararigas, G., additional, Nguyen, B. T., additional, Jarry, H., additional, Regitz-Zagrosek, V., additional, Van Bilsen, M., additional, Daniels, A., additional, Munts, C., additional, Janssen, B. J. A., additional, Van Der Vusse, G. J., additional, Van Nieuwenhoven, F. A., additional, Montalvo, C., additional, Villar, A. V., additional, Merino, D., additional, Garcia, R., additional, Llano, M., additional, Ares, M., additional, Hurle, M. A., additional, Nistal, J. F., additional, Dembinska-Kiec, A., additional, Beata Kiec-Wilk, B. K. W., additional, Anna Polus, A. P., additional, Urszula Czech, U. C., additional, Tatiana Konovaleva, T. K., additional, Gerd Schmitz, G. S., additional, Bertrand, L., additional, Balteau, M., additional, Timmermans, A., additional, Viollet, B., additional, Sakamoto, K., additional, Feron, O., additional, Horman, S., additional, Vanoverschelde, J. L., additional, Beauloye, C., additional, De Meester, C., additional, Martinez, E., additional, Martin, R., additional, Miana, M., additional, Jurado, R., additional, Gomez-Hurtado, N., additional, Bartolome, M. V., additional, San Roman, J. A., additional, Lahera, V., additional, Nieto, M. L., additional, Cachofeiro, V., additional, Rochais, F., additional, Sturny, R., additional, Mesbah, K., additional, Miquerol, L., additional, Kelly, R. G., additional, Messaoudi, S., additional, Gravez, B., additional, Tarjus, A., additional, Pelloux, V., additional, Samuel, J. L., additional, Delcayre, C., additional, Launay, J. M., additional, Clement, K., additional, Farman, N., additional, Jaisser, F., additional, Hadyanto, L., additional, Castellani, C., additional, Vescovo, G., additional, Ravara, B., additional, Tavano, R., additional, Pozzobon, M., additional, De Coppi, P., additional, Papini, E., additional, Vettor, R., additional, Thiene, G., additional, Angelini, A., additional, Meloni, M., additional, Caporali, A., additional, Cesselli, D., additional, Fortunato, O., additional, Avolio, E., additional, Schindler, R., additional, Simrick, S., additional, Brand, T., additional, Smart, N. S., additional, Herman, A., additional, Roura Ferrer, S., additional, Rodriguez Bago, J., additional, Soler-Botija, C., additional, Pujal, J. M., additional, Galvez-Monton, C., additional, Prat-Vidal, C., additional, Llucia-Valldeperas, A., additional, Blanco, J., additional, Bayes-Genis, A., additional, Foldes, G., additional, Maxime, M., additional, Ali, N. N., additional, Schneider, M. D., additional, Harding, S. E., additional, Reni, C., additional, Mangialardi, G., additional, De Pauw, A., additional, Sekkali, B., additional, Friart, A., additional, Ding, H., additional, Graffeuil, A., additional, Catalucci, D., additional, Balligand, J. L., additional, Azibani, F., additional, Tournoux, F., additional, Schlossarek, S., additional, Polidano, E., additional, Fazal, L., additional, Merval, R., additional, Carrier, L., additional, Chatziantoniou, C., additional, Buyandelger, B., additional, Linke, W., additional, Zou, P., additional, Kostin, S., additional, Ku, C., additional, Felkin, L., additional, Birks, E., additional, Barton, P., additional, Sattler, M., additional, Knoell, R., additional, Schroder, K., additional, Benkhoff, S., additional, Shimokawa, H., additional, Grisk, O., additional, Brandes, R. P., additional, Parepa, I. R., additional, Mazilu, L., additional, Suceveanu, A. I., additional, Suceveanu, A., additional, Rusali, L., additional, Cojocaru, L., additional, Matei, L., additional, Toringhibel, M., additional, Craiu, E., additional, Pires, A. L., additional, Pinho, M., additional, Pinho, S., additional, Sena, C., additional, Seica, R., additional, Leite-Moreira, A., additional, Dabroi, F., additional, Schiaffino, S., additional, Kiseleva, E., additional, Krukov, N., additional, Nikitin, O., additional, Ardatova, L., additional, Mourouzis, I., additional, Pantos, C., additional, Kokkinos, A. D., additional, Cokkinos, D. V., additional, Scoditti, E., additional, Massaro, M., additional, Carluccio, M. A., additional, Pellegrino, M., additional, Calabriso, N., additional, Gastaldelli, A., additional, Storelli, C., additional, De Caterina, R., additional, Lindner, D., additional, Zietsch, C., additional, Schultheiss, H.-P., additional, Tschope, C., additional, Westermann, D., additional, Everaert, B. R., additional, Nijenhuis, V. J., additional, Reith, F. C. M., additional, Hoymans, V. Y., additional, Timmermans, J. P., additional, Vrints, C. J., additional, Simova, I., additional, Mateev, H., additional, Katova, T., additional, Haralanov, L., additional, Dimitrov, N., additional, Mironov, N., additional, Golitsyn, S. P., additional, Sokolov, S. F., additional, Yuricheva, Y. U. A., additional, Maikov, E. B., additional, Shlevkov, N. B., additional, Rosenstraukh, L. V., additional, Chazov, E. I., additional, Radosinska, J., additional, Knezl, V., additional, Benova, T., additional, Slezak, J., additional, Urban, L., additional, Tribulova, N., additional, Virag, L., additional, Kristof, A., additional, Kohajda, Z. S., additional, Szel, T., additional, Husti, Z., additional, Baczko, I., additional, Jost, N., additional, Varro, A., additional, Sarusi, A., additional, Farkas, A. S., additional, Orosz, S. Z., additional, Forster, T., additional, Farkas, A., additional, Zakhrabova-Zwiauer, O. M., additional, Hardziyenka, M., additional, Nieuwland, R., additional, Tan, H. L., additional, Raaijmakers, A. J. A., additional, Bourgonje, V. J. A., additional, Kok, G. J. M., additional, Van Veen, A. A. B., additional, Anderson, M. E., additional, Vos, M. A., additional, Bierhuizen, M. F. A., additional, Benes, J., additional, Sebestova, B., additional, Ghouri, I. A., additional, Kemi, O. J., additional, Kelly, A., additional, Burton, F. L., additional, Smith, G. L., additional, Ozdemir, S., additional, Acsai, K., additional, Doisne, N., additional, Van Der Nagel, R., additional, Beekman, H. D. M., additional, Van Veen, T. A. B., additional, Sipido, K. R., additional, Antoons, G., additional, Harmer, S. C., additional, Mohal, J. S., additional, Kemp, D., additional, Tinker, A., additional, Beech, D., additional, Burley, D. S., additional, Cox, C. D., additional, Wann, K. T., additional, Baxter, G. F., additional, Wilders, R., additional, Verkerk, A., additional, Fragkiadaki, P., additional, Germanakis, G., additional, Tsarouchas, K., additional, Tsitsimpikou, C., additional, Tsardi, M., additional, George, D., additional, Tsatsakis, A., additional, Rodrigues, P., additional, Barros, C., additional, Najmi, A. K., additional, Khan, V., additional, Akhtar, M., additional, Pillai, K. K., additional, Mujeeb, M., additional, Aqil, M., additional, Bayliss, C. R., additional, Messer, A. E., additional, Leung, M.-C., additional, Ward, D., additional, Van Der Velden, J., additional, Poggesi, C., additional, Redwood, C. S., additional, Marston, S., additional, Vite, A., additional, Gandjbakhch, E., additional, Gary, F., additional, Fressart, V., additional, Leprince, P., additional, Fontaine, G., additional, Komajda, M., additional, Charron, P., additional, Villard, E., additional, Falcao-Pires, I., additional, Gavina, C., additional, Hamdani, N., additional, Stienen, G. J. M., additional, Niessens, H. W. M., additional, Leite-Moreira, A. F., additional, Paulus, W. J., additional, Memo, M., additional, Marston, S. B., additional, Vafiadaki, E., additional, Qian, J., additional, Arvanitis, D. A., additional, Sanoudou, D., additional, Kranias, E. G., additional, Elmstedt, N., additional, Lind, B., additional, Ferm-Widlund, K., additional, Westgren, M., additional, Brodin, L.-A., additional, Mansfield, C., additional, West, T., additional, Ferenczi, M., additional, Wijnker, P. J. M., additional, Foster, D. B., additional, Coulter, A., additional, Frazier, A., additional, Murphy, A. M., additional, Shah, M., additional, Sikkel, M. B., additional, Desplantez, T., additional, Collins, T. P., additional, O' Gara, P., additional, Lyon, A. R., additional, Macleod, K. T., additional, Ottesen, A. H., additional, Louch, W. E., additional, Carlson, C., additional, Landsverk, O. J. B., additional, Stridsberg, M., additional, Sjaastad, I., additional, Oie, E., additional, Omland, T., additional, Christensen, G., additional, Rosjo, H., additional, Cartledge, J., additional, Clark, L. A., additional, Ibrahim, M., additional, Siedlecka, U., additional, Navaratnarajah, M., additional, Yacoub, M. H., additional, Camelliti, P., additional, Terracciano, C. M., additional, Chester, A., additional, Gonzalez-Tendero, A., additional, Torre, I., additional, Garcia-Garcia, F., additional, Dopazo, J., additional, Gratacos, E., additional, Taylor, D., additional, Bhandari, S., additional, Seymour, A.-M., additional, Fliegner, D., additional, Jost, J., additional, Bugger, H., additional, Ventura-Clapier, R., additional, Carpi, A., additional, Campesan, M., additional, Canton, M., additional, Menabo, R., additional, Pelicci, P. G., additional, Giorgio, M., additional, Di Lisa, F., additional, Hancock, M., additional, Venturini, A., additional, Al-Shanti, N., additional, Stewart, C., additional, Ascione, R., additional, Angelini, G., additional, Suleiman, M.-S., additional, Kravchuk, E., additional, Grineva, E., additional, Galagudza, M., additional, Kostareva, A., additional, Bairamov, A., additional, Krychtiuk, K. A., additional, Watzke, L., additional, Kaun, C., additional, Demyanets, S., additional, Pisoni, J., additional, Kastl, S. P., additional, Huber, K., additional, Maurer, G., additional, Wojta, J., additional, Speidl, W. S., additional, Varga, Z. V., additional, Farago, N., additional, Zvara, A., additional, Kocsis, G. F., additional, Pipicz, M., additional, Csonka, C., additional, Csont, T., additional, Puskas, G. L., additional, Ferdinandy, P., additional, Klevstigova, M., additional, Silhavy, J., additional, Manakov, D., additional, Papousek, F., additional, Novotny, J., additional, Pravenec, M., additional, Kolar, F., additional, Novakova, O., additional, Novak, F., additional, Neckar, J., additional, Barallobre-Barreiro, J., additional, Didangelos, A., additional, Yin, X., additional, Fernandez-Caggiano, M., additional, Drozdov, I., additional, Willeit, P., additional, Domenech, N., additional, Mayr, M., additional, Lemoine, S., additional, Allouche, S., additional, Coulbault, L., additional, Galera, P., additional, Gerard, J. L., additional, Hanouz, J. L., additional, Suveren, E., additional, Whiteman, M., additional, Studneva, I. M., additional, Pisarenko, O., additional, Shulzhenko, V., additional, Serebryakova, L., additional, Tskitishvili, O., additional, Timoshin, A., additional, Fauconnier, J., additional, Meli, A. C., additional, Thireau, J., additional, Roberge, S., additional, Lompre, A. M., additional, Jacotot, E., additional, Marks, A. M., additional, Lacampagne, A., additional, Dietel, B., additional, Altendorf, R., additional, Daniel, W. G., additional, Kollmar, R., additional, Garlichs, C. D., additional, Parente, V., additional, Balasso, S., additional, Pompilio, G., additional, Colombo, G., additional, Milano, G., additional, Squadroni, L., additional, Cotelli, F., additional, Pozzoli, O., additional, Capogrossi, M. C., additional, Ajiro, Y., additional, Saegusa, N., additional, Iwade, K., additional, Giles, W. R., additional, Stafforini, D. M., additional, Spitzer, K. W., additional, Sirohi, R., additional, Candilio, L., additional, Babu, G., additional, Roberts, N., additional, Lawrence, D., additional, Sheikh, A., additional, Kolvekar, S., additional, Yap, J., additional, Hausenloy, D. J., additional, Yellon, D. M., additional, Aslam, M., additional, Rohrbach, S., additional, Schlueter, K.-D., additional, Piper, H. M., additional, Noll, T., additional, Guenduez, D., additional, Malinova, L., additional, Ryabukho, V. P., additional, Lyakin, D. V., additional, Denisova, T. P., additional, Montoro-Garcia, S., additional, Shantsila, E., additional, Lip, G. Y. H., additional, Kalaska, B., additional, Sokolowska, E., additional, Kaminski, K., additional, Szczubialka, K., additional, Kramkowski, K., additional, Mogielnicki, A., additional, Nowakowska, M., additional, Buczko, W., additional, Stancheva, N., additional, Mekenyan, E., additional, Gospodinov, K., additional, Tisheva, S., additional, Darago, A., additional, Rutkai, I., additional, Kalasz, J., additional, Czikora, A., additional, Orosz, P., additional, Bjornson, H. D., additional, Edes, I., additional, Papp, Z., additional, Toth, A., additional, Riches, K., additional, Warburton, P., additional, O'regan, D. J., additional, Ball, S. G., additional, Turner, N. A., additional, Wood, I. C., additional, Porter, K. E., additional, Kogaki, S., additional, Ishida, H., additional, Nawa, N., additional, Takahashi, K., additional, Baden, H., additional, Ichimori, H., additional, Uchikawa, T., additional, Mihara, S., additional, Miura, K., additional, Ozono, K., additional, Lugano, R., additional, Padro, T., additional, Garcia-Arguinzonis, M., additional, Badimon, L., additional, Ferraro, F., additional, Viner, R., additional, Ho, J., additional, Cutler, D., additional, Matchkov, V., additional, Aalkjaer, C., additional, Krijnen, P. A. J., additional, Hahn, N. E., additional, Kholova, I., additional, Sipkens, J. A., additional, Van Alphen, F. P., additional, Simsek, S., additional, Schalkwijk, C. G., additional, Van Buul, J. D., additional, Van Hinsbergh, V. W. M., additional, Niessen, H. W. M., additional, Caro, C. G., additional, Seneviratne, A., additional, Monaco, C., additional, Hou, D., additional, Singh, J., additional, Gilson, P., additional, Burke, M. G., additional, Heraty, K. B., additional, Krams, R., additional, Coppola, G., additional, Albrecht, K., additional, Schgoer, W., additional, Wiedemann, D., additional, Bonaros, N., additional, Steger, C., additional, Theurl, M., additional, Stanzl, U., additional, Kirchmair, R., additional, Amadesi, S., additional, Spinetti, G., additional, Cangiano, E., additional, Valgimigli, M., additional, Miller, A. M., additional, Cardinali, A., additional, Vierlinger, K., additional, Pagano, G., additional, Liccardo, D., additional, Zincarelli, C., additional, Femminella, G. D., additional, Lymperopoulos, A., additional, De Lucia, C., additional, Koch, W. J., additional, Leosco, D., additional, Rengo, G., additional, Hinkel, R., additional, Husada, W., additional, Trenkwalder, T., additional, Di, Q., additional, Lee, S., additional, Petersen, B., additional, Bock-Marquette, I., additional, Niemann, H., additional, Di Maio, M., additional, Kupatt, C., additional, Nourian, M., additional, Yassin, Z., additional, Kelishadi, R., additional, Memarian, S. H., additional, Heidari, A., additional, Leuner, A., additional, Poitz, D. M., additional, Brunssen, C., additional, Ravens, U., additional, Strasser, R. H., additional, Morawietz, H., additional, Vogt, F., additional, Grahl, A., additional, Flege, C., additional, Marx, N., additional, Borinski, M., additional, De Geest, B., additional, Jacobs, F., additional, Muthuramu, I., additional, Gordts, S. C., additional, Van Craeyveld, E., additional, Herijgers, P., additional, Weinert, S., additional, Medunjanin, S., additional, Herold, J., additional, Schmeisser, A., additional, Braun-Dullaeus, R. C., additional, Wagner, A. H., additional, Moeller, K., additional, Adolph, O., additional, Schwarz, M., additional, Schwale, C., additional, Bruehl, C., additional, Nobiling, R., additional, Wieland, T., additional, Schneider, S. W., additional, Hecker, M., additional, Cross, A., additional, Strom, A., additional, Cole, J., additional, Goddard, M., additional, Hultgardh-Nilsson, A., additional, Nilsson, J., additional, Mauri, C., additional, Mitkovskaya, N. P., additional, Kurak, T. A., additional, Oganova, E. G., additional, Shkrebneva, E. I., additional, Kot, Z. H. N., additional, Statkevich, T. V., additional, Molica, F., additional, Burger, F., additional, Matter, C. M., additional, Thomas, A., additional, Staub, C., additional, Zimmer, A., additional, Cravatt, B., additional, Pacher, P., additional, Steffens, S., additional, Blanco, R., additional, Sarmiento, R., additional, Parisi, C., additional, Fandino, S., additional, Blanco, F., additional, Gigena, G., additional, Szarfer, J., additional, Rodriguez, A., additional, Garcia Escudero, A., additional, Riccitelli, M. A., additional, Wantha, S., additional, Simsekyilmaz, S., additional, Megens, R. T., additional, Van Zandvoort, M. A., additional, Liehn, E., additional, Zernecke, A., additional, Klee, D., additional, Weber, C., additional, Soehnlein, O., additional, Lima, L. M., additional, Carvalho, M. G., additional, Gomes, K. B., additional, Santos, I. R., additional, Sousa, M. O., additional, Morais, C. A. S., additional, Oliveira, S. H. V., additional, Gomes, I. F., additional, Brandao, F. C., additional, Lamego, M. R. A., additional, Fornai, L., additional, Kiss, A., additional, Giskes, F., additional, Eijkel, G., additional, Fedrigo, M., additional, Valente, M. L., additional, Heeren, R. M. A., additional, Grdinic, A., additional, Vojvodic, D., additional, Djukanovic, N., additional, Grdinic, A. G., additional, Obradovic, S., additional, Majstorovic, I., additional, Rusovic, S., additional, Vucinic, Z., additional, Tavciovski, D., additional, Ostojic, M., additional, Lai, S.-C., additional, Chen, M.-Y., additional, Wu, H.-T., additional, Gouweleeuw, L., additional, Oberdorf-Maass, S. U., additional, De Boer, R. A., additional, Van Gilst, W. H., additional, Maass, A. H., additional, Van Gelder, I. C., additional, Benard, L., additional, Li, C., additional, Warren, D., additional, Shanahan, C. M., additional, Zhang, Q. P., additional, Bye, A., additional, Vettukattil, R., additional, Aspenes, S. T., additional, Giskeodegaard, G., additional, Gribbestad, I. S., additional, Wisloff, U., additional, Bathen, T. F., additional, Cubedo, J., additional, Alonso, R., additional, Mata, P., additional, Ivic, I., additional, Vamos, Z., additional, Cseplo, P., additional, Kosa, D., additional, Torok, O., additional, Hamar, J., additional, Koller, A., additional, Norita, K., additional, De Noronha, S. V., additional, Sheppard, M. N., additional, Amat-Roldan, I., additional, Iruretagoiena, I., additional, Psilodimitrakopoulos, S., additional, Crispi, F., additional, Artigas, D., additional, Loza-Alvarez, P., additional, Harrison, J. C., additional, Smart, S. D., additional, Besely, E. H., additional, Kelly, J. R., additional, Yao, Y., additional, Sammut, I. A., additional, Hoepfner, M., additional, Kuzyniak, W., additional, Sekhosana, E., additional, Hoffmann, B., additional, Litwinski, C., additional, Pries, A., additional, Ermilov, E., additional, Fontoura, D., additional, Lourenco, A. P., additional, Vasques-Novoa, F., additional, Pinto, J. P., additional, Roncon-Albuquerque, R., additional, Oyeyipo, I. P., additional, Olatunji, L. A., additional, Usman, T. O., additional, Olatunji, V. A., additional, Bacova, B., additional, Viczenczova, C., additional, Dosenko, V., additional, Goncalvesova, E., additional, Vanrooyen, J., additional, Maulik, S. K., additional, Seth, S., additional, Dinda, A. K., additional, Jaiswal, A., additional, Mearini, G., additional, Khajetoorians, D., additional, Kraemer, E., additional, Gedicke-Hornung, C., additional, Precigout, G., additional, Eschenhagen, T., additional, Voit, T., additional, Garcia, L., additional, Lorain, S., additional, Mendes-Ferreira, P., additional, Maia-Rocha, C., additional, Adao, R., additional, Cerqueira, R. J., additional, Mendes, M. J., additional, Castro-Chaves, P., additional, De Keulenaer, G. W., additional, Bras-Silva, C., additional, Ruiter, G., additional, Wong, Y. Y., additional, Lubberink, M., additional, Knaapen, P., additional, Raijmakers, P., additional, Lammertsma, A. A., additional, Marcus, J. T., additional, Westerhof, N., additional, Van Der Laarse, W. J., additional, Vonk-Noordegraaf, A., additional, Steinbronn, N., additional, Koch, E., additional, Steiner, G., additional, Berezin, A., additional, Lisovaya, O. A., additional, Soldatova, A. M., additional, Kuznetcov, V. A., additional, Yenina, T. N., additional, Rychkov, A. Y. U., additional, Shebeko, P. V., additional, Altara, R., additional, Hessel, M. H. M., additional, Hermans, J. J. R., additional, Blankesteijn, W. M., additional, Berezina, T. A., additional, Seden, V., additional, Bonanad, C., additional, Nunez, J., additional, Navarro, D., additional, Chilet, M. F., additional, Sanchis, F., additional, Bodi, V., additional, Minana, G., additional, Chaustre, F., additional, Forteza, M. J., additional, Llacer, A., additional, Galasso, G., additional, Ferrara, N., additional, Akhmedov, A., additional, Klingenberg, R., additional, Brokopp, C., additional, Hof, D., additional, Zoller, S., additional, Corti, R., additional, Gay, S., additional, Von Eckardstein, A., additional, Hoerstrup, S. P., additional, Luescher, T. F., additional, Heijman, J., additional, Zaza, A., additional, Johnson, D. M., additional, Rudy, Y., additional, Peeters, R. L. M., additional, Volders, P. G. A., additional, Westra, R. L., additional, Fujita, S., additional, Okamoto, R., additional, Taniguchi, M., additional, Konishi, K., additional, Goto, I., additional, Sugimoto, K., additional, Nakamura, M., additional, Shiraki, K., additional, Buechler, C., additional, and Ito, M., additional

Published
2012
Full Text
View/download PDF

188. Effect of Nesiritide in Patients with Acute Decompensated Heart Failure

Author

O'Connor, C.M., primary, Starling, R.C., additional, Hernandez, A.F., additional, Armstrong, P.W., additional, Dickstein, K., additional, Hasselblad, V., additional, Heizer, G.M., additional, Komajda, M., additional, Massie, B.M., additional, McMurray, J.J.V., additional, Nieminen, M.S., additional, Reist, C.J., additional, Rouleau, J.L., additional, Swedberg, K., additional, Adams, K.F., additional, Anker, S.D., additional, Atar, D., additional, Battler, A., additional, Botero, R., additional, Bohidar, N.R., additional, Butler, J., additional, Clausell, N., additional, Corbalán, R., additional, Costanzo, M.R., additional, Dahlstrom, U., additional, Deckelbaum, L.I., additional, Diaz, R., additional, Dunlap, M.E., additional, Ezekowitz, J.A., additional, Feldman, D., additional, Felker, G.M., additional, Fonarow, G.C., additional, Gennevois, D., additional, Gottlieb, S.S., additional, Hill, J.A., additional, Hollander, J.E., additional, Howlett, J.G., additional, Hudson, M.P., additional, Kociol, R.D., additional, Krum, H., additional, Laucevicius, A., additional, Levy, W.C., additional, Méndez, G.F., additional, Metra, M., additional, Mittal, S., additional, Oh, B.-H., additional, Pereira, N.L., additional, Ponikowski, P., additional, Tang, W.H.W., additional, Tanomsup, S., additional, Teerlink, J.R., additional, Triposkiadis, F., additional, Troughton, R.W., additional, Voors, A.A., additional, Whellan, D.J., additional, Zannad, F., additional, and Califf, R.M., additional

Published
2011
Full Text
View/download PDF

193. Vasopeptidase inhibition with omapatrilat in chronic heart failure: Acute and long-term hemodynamic and neurohumoral effects

Author

UCL - MD/MINT - Département de médecine interne, UCL - (SLuc) Service de pathologie cardiovasculaire, McClean, DR, Ikram, H, Mehta, S, Heywood, JT, Rousseau, Michel, Niederman, AL, Sequeira, RF, Fleck, E., Singh, SN, Coutu, B, Hanrath, P., Komajda, M, Bryson, CC, Qian, CL, Hanyok, JJ, UCL - MD/MINT - Département de médecine interne, UCL - (SLuc) Service de pathologie cardiovasculaire, McClean, DR, Ikram, H, Mehta, S, Heywood, JT, Rousseau, Michel, Niederman, AL, Sequeira, RF, Fleck, E., Singh, SN, Coutu, B, Hanrath, P., Komajda, M, Bryson, CC, Qian, CL, and Hanyok, JJ

Abstract

OBJECTIVES We investigated the acute and long-term hemodynamic and neurohumoral effects of the vasopeptidase inhibitor omapatrilat in human heart failure. BACKGROUND Angiotensin-converting enzyme (ACE) inhibition constitutes a major advance in the treatment of chronic heart failure (CHF). Simultaneous inhibition of both neutral endopeptidase and ACE with omapatrilat may represent a new treatment strategy in CHF. METHODS Three hundred and sixty-nine patients with symptomatic heart failure were randomized to double-blind treatment with omapatrilat (first 190 patients: 2.5 mg, 5 mg or 10 mg; last 179 patients: 2.5 mg, 20 mg or 40 mg once daily) for 12 weeks. RESULTS Acutely, the 10 mg, 20 mg and 40 rug doses of omapatrilat produced greater reductions in pulmonary capillary, wedge pressure (PCWP), systolic blood pressure (SBP) and systemic vascular resistance compared with 2.5 mg. Higher doses were associated with greater increases in vasodilator and natriuretic peptides, in addition to ACE inhibition. After 12 weeks, omapatrilat 20 mg and 40 mg showed greater fills from baseline in PCWP (40 mg: 0 h to 12 h average change -7.3 +/- 0.8 mm Hg) and SBP (40 mg: -11.7 +/- 1.7 min Hg) than 2.5 mg (both p < 0.01 vs. 2.5 mg). The incidence of adverse experiences and patient withdrawal were similar in all groups. CONCLUSIONS In CHF, the acute hemodynamic benefit seen with higher doses of omapatrilat was associated with increases in plasma vasodilator and natriuretic peptide levels in addition to ACE inhibition. After 12 weeks, the hemodynamic benefit was maintained. Omapatrilat may be a promising new agent in CHF.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results